AUSTIN, Texas, Dec. 9, 2015 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it will host a Key Opinion Leader breakfast on Friday, December 11, 2015 from 8am-9:30am Eastern Time in New York City.
The meeting will feature three experts in gynecology and gynecological oncology: Farr R. Nezhat, MD FACOG FACS, Michael D. Randell, MD FACOG, and Judith K. Wolf, MD, as well as members of the Vermillion executive management team.
The event is intended for institutional investors and sell-side analysts only. If you would like to attend, please contact Mac MacDonald at 212-915-2567 or via e-mail at firstname.lastname@example.org.
Dr. Farr R. Nezhat is the Director of the Minimally Invasive Gynecologic Surgery and Robotics (MIGSR) Division and Director of the MIGSR Fellowship Program in the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology at the Mount Sinai St. Luke's and Roosevelt Hospitals. He also serves as Director of Minimally Invasive Gynecologic Surgery in the Department of Obstetrics and Gynecology at Winthrop University Hospital, Professor in the Department of Obstetrics, Gynecology and Reproductive Science at Icahn School of Medicine at Mount Sinai, and Adjunct Professor at Stony Brook University School of Medicine.
Dr. Nezhat is a world-renowned authority in advanced laparoscopic and robotic surgery for the treatment of gynecological cancers and complex benign conditions. He is internationally recognized for his pioneering work in developing minimally invasive surgical techniques and establishing evidence-based protocols for management and treatment of different pelvic disorders such as endometriosis, ovarian cysts and uterine myoma. His main areas of interest and research include early detection and treatment of early and advanced ovarian cancer as well as cancer arising in endometriosis.
Dr. Michael D. Randell is a board certified Obstetrician and Gynecologist in private practice in Atlanta, Georgia. He serves on the Medical Staff in the Department of Obstetrics and Gynecology at Northside Hospital, one of the largest comprehensive women's health care facilities in the United States. He received his training in Obstetrics and Gynecology at the University of Miami/Jackson Memorial Medical Center, one of the largest hospitals for obstetrics in the United States.
Dr. Randell is an expert in laparoscopic and robotic surgery. His special clinical interests are in medical complications of pregnancy, management of abnormal Pap smears, vaginal and urogynecological surgery, and operative laparoscopy. His research interests in managing cancer during pregnancy, the treatment of atypical Pap smears, and the effects of barometric pressure changes on the initiation of labor, have led to award winning presentations at scientific and medical meetings.
Dr. Judith Wolf is the former Chief of Surgery at Banner MD Anderson Cancer Center in Arizona. She was an Adjunct Professor at the University of Texas MD Anderson Cancer Center in Houston and a Clinical Professor in the Division of Clinical Education AZDOM. She was also Chairman of the Medical and Scientific Advisory Board of the National Ovarian Cancer Coalition. Dr. Wolf joined Vermillion as Chief Medical Officer in September 2014.
Dr. Wolf is a renowned expert in the field of gynecologic cancer and is double Board Certified in both Obstetrics and Gynecology and Gynecologic Oncology. She has previously served as a Tenured Professor in Gynecologic Oncology at the University of Texas MD Anderson Cancer Center from 1995-2011. Her clinical and research interests are in the treatment and surgical management of gynecologic cancers, specifically ovarian cancer, with a focus on minimally invasive procedures and medical pelvic and abdominal surgeries.
About Vermillion Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic disease. The company's lead diagnostics in the United States, OVA1®, and in the European Union, Overa®, are blood tests for pre-surgical assessment of ovarian tumors for malignancy, each using an innovative algorithmic approach. Overa and OVA1, which was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, represent a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.
CONTACT: Michael Wood LifeSci Advisors LLC 646-597-6983 email@example.com
SOURCE Vermillion, Inc.